-$0.16 EPS Expected for Senseonics Holdings, Inc. (NASDAQ:SENS) This Quarter

Equities analysts expect Senseonics Holdings, Inc. (NASDAQ:SENS) to announce ($0.16) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Senseonics’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.13). Senseonics posted earnings per share of ($0.14) in the same quarter last year, which suggests a negative year-over-year growth rate of 14.3%. The firm is expected to issue its next earnings results on Thursday, November 14th.

On average, analysts expect that Senseonics will report full year earnings of ($0.66) per share for the current financial year, with EPS estimates ranging from ($0.72) to ($0.59). For the next year, analysts expect that the firm will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.75) to ($0.38). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Senseonics.

Senseonics (NASDAQ:SENS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). The business had revenue of $4.61 million for the quarter, compared to analyst estimates of $4.52 million.

Shares of SENS traded down $0.02 during mid-day trading on Friday, reaching $1.06. The stock had a trading volume of 3,516,610 shares, compared to its average volume of 1,807,491. Senseonics has a 12 month low of $0.92 and a 12 month high of $4.89. The business has a fifty day moving average of $1.07 and a 200 day moving average of $1.84.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Story: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.